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Abstract
Background: More than 1 million tuberculosis (TB) patients are receiving the standard anti-TB treatment provided by 
China National Tuberculosis Prevention and Control Scheme (CNTS) in China every year. Adverse reactions (ADRs) 
induced by anti-TB drugs could both do harm to patients and lead to anti-TB treatment failure. The ADACS aimed to 
explore ADRs' incidences, prognoses, economical and public health impacts for TB patients and TB control, and build a 
DNA bank of TB patients.
Methods/Design: Multiple study designs were adopted. Firstly, a prospective cohort with 4488 sputum smears 
positive pulmonary tuberculosis patients was established. Patients were followed up for 6-9 months in 52 counties of 
four regions. Those suspected ADRs should be checked and confirmed by Chinese State Food and Drug Administration 
(SFDA). Secondly, if the suspected ADR was anti-TB drug induced liver injury (ATLI), a nested case-control study would 
be performed which comprised choosing a matched control and doing a plus questionnaire inquiry. Thirdly, health 
economical data of ADRs would be collected to analyze financial burdens brought by ADRs and cost-effectiveness of 
ADRs' treatments. Fourthly, a drop of intravenous blood for each patient was taken and saved in FTA card for DNA 
banking and genotyping. Finally, the demographic, clinical, environmental, administrative and genetic data would be 
merged for the comprehensive analysis.
Discussion: ADACS will give an overview of anti-TB drugs induced ADRs' incidences, risk factors, treatments, 
prognoses, and clinical, economical and public health impacts for TB patients applying CNTS regimen in China, and 
provide suggestions for individualized health care and TB control policy.
Background
Tuberculosis (TB) is one of the most common infectious
diseases globally. According to WHO reports, there were
an estimated 9.3 million incident cases and 13.7 million
prevalent cases of TB in 2007[1]. China is the second
highest TB burden country in the world, only next to
India. To control TB epidemic, China established China
National Tuberculosis Prevention and Control Scheme
(CNTS) in 1990, and started implementing directly
observed treatment strategy (DOTS) since 1991. Nowa-
days DOTS has covered all population in China [1], and
became the major TB control access. The key component
of DOTS strategy is the standard anti-TB short course
chemotherapy regimen. The regimen which requires con-
tinually taking drug combinations of Isoniazid(H), Rifam-
picin (R), Pyrazinamide(Z), Ethambutol(E) and
Streptomycin(S) every other day for 6-9 months, is rec-
ommended by WHO and currently used in the majority
of high TB burden countries[2]. With loans and grants
from World Bank and UK Department for international
development, Chinese government promises that all spu-
tum smear positive TB patients could get the standard
therapy freely from local Center for Disease Control and
Prevention (CDC) [3].
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Patient should come to CDC to get drugs monthly and
take drugs at home with direct observation by a village or
town clinic doctor as the supervisor. Nowadays, nearly
100,000 new detected smear positive TB patients are
going through this therapy every year [1]. Drugs in the
therapy (H, R, Z, E, S), in addition to their role of killing
and containing Mycobacterium effectively, could cause
different kinds of adverse reactions (ADRs), such as hepa-
totoxic reaction, gastro-intestinal discomfort, drug
allergy, arthralgia, etc. Those ADRs are regarded as one
of the major causes of incompliance of anti-TB treatment
[4,5]. They may lead to final termination of TB treatment
and severe ADRs outcomes like liver failure or death as
well. As to the ADRs overall incidence, no consensus has
been reached. Different studies may vary from 5.5% to
57.8% according to different populations and ADRs defi-
nitions [6-11]. Generally speaking, studies with larger
sample tend to report relatively lower incidence which
may be related to their retrospective study design. In
China, our previous systematic review showed that the
integrated ADRs overall incidence was around 12.6%
[12]. But most of individual studies in our systematic
review had small sample size, oversensitive ADRs diag-
nostic standards and were done in general hospitals. Very
few studies focused on CNTS therapy induced ADRs.
The possible environmental and genetic factors of anti-
TB induced ADRs have always been the matter of con-
cern. It is well documented that the risk of ADR increases
with age [13-16], malnutrition [17-20], and history of
hepatitis [16,21]. In addition, a large number of other
environmental factors have been hypothesized to be
associated with ADRs such as human immunodeficiency
virus infection [20,22-25] and hepatitis C virus infection
[22]. But questions remain about the effects of these
exposures either because previous studies have shown
mixed results (Caucasian[26], gender[26,27], high alcohol
intake[18,28], Hepatitis B virus infection[15,29-31]) or
because they have been retrospective and susceptible to a
variety of biases (Severity of TB[29,32]). Genetic factors
like isoniazid-metablising enzyme gene polymorphisms
were studied a lot but these studies also showed inconsis-
tent results [33]. Until now, the comprehensive study for
environmental, genetic, clinical and administrative fac-
tors has not been reported.
Besides, there is a typical clinical practice in China: pre-
scribing liver protected drugs to patients before they ini-
tiate the anti-TB treatment in order to lower the risk of
hepatotoxicity. Usually those drugs will be taken for 2
months or through the whole anti-TB treatment. A num-
ber of drugs using for curing or relieving symptoms of
drug-induced hepatitis are used in this kind of prevention
although neither their effects nor safety have been con-
vincingly approved in preventive use[34]. It brings
patients extra economical burden, yet with unconfirmed
effect and risks of new ADRs induced by those liver pro-
tective drugs. We intended to study those environmental,
genetic and clinical factors comprehensively to help
develop individualized anti-TB regimen in the future and
assess the necessity of preventive drug use.
Although it is well known that those ADRs will do great
harm to patients, the economical impacts of ADRs are
seldom studied. Different kinds of ADRs call for different
kinds of examinations and treatments which differ in
costs. Hospitalizing, transport, nutrition supplement,
loss of working time and anti-TB drug replacements will
also lead to considerable amount of costs. Another nega-
tive impact of anti-TB drug induced ADR is that patient
may have regimen change, regimen suspension or tempo-
rarily interruption after ADR happens. Thus it may not
only cause personal anti-TB treatment failure, but will
also affect TB epidemic control since the patient still
remains in Mycobacterium transmittable status and
could possibly infects 10-15 more people in 12
months[35]. Therefore, getting an overview of those clin-
ical, economical and public health impacts for TB
patients and TB control will be quite meaningful.
Methods/Design
Overview and objectives
The ADACS is a prospective longitudinal study of anti-
tuberculosis drugs induced adverse reactions based on a
multi-center cohort of 4488 pulmonary tuberculosis
patients receiving China National Tuberculosis Preven-
tion and Control Scheme treatment.
The aim of ADACS was to recognize incidences, prog-
noses, impacts, and risk factors of anti-tuberculosis drugs
induced ADRs in CNTS, and provide individualized
health care and TB control policy suggestions. The major
objectives of ADACS were:
1) To determine the incidences of anti-tuberculosis
drugs induced ADRs in CNTS and the harm to TB
patients in China.
2) To evaluate the impacts of anti-tuberculosis drugs
induced ADRs on China tuberculosis control.
3) To explore genetic and environmental risk factors
relevant with anti-tuberculosis induced ADRs and their
interactions.
4) To investigate the usage and effect of liver protective
drugs.
5) To evaluate the health economic burden of anti-
tuberculosis induced ADRs and their treatments.
6) To build a TB patient DNA samples bank for future
research.
Study area selection
The study fields were selected to meet those criteria: 1)
including provinces located in north and south, west and
east of China; 2) including provinces comparativelyXia et al. BMC Public Health 2010, 10:267
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developed and developing in economic status; 3) the
selected provinces had performed DOTS well; 4) CDC of
counties in the selected provinces had laboratories to do
the study required examinations independently.
Four districts, Zhejiang Province, Jilin Province,
Guangxi Zhuang Autonomous Region, and Chongqing
Municipality were chosen ultimately with expert consul-
tancy. Zhejiang, Guangxi, Chongqing represented south
of China, Jilin represents north of China; Zhejiang repre-
sented east of China, Guangxi and Chongqing repre-
sented west of China; Zhejiang represented economic
developed districts and Chongqing, Jilin, Guangxi repre-
sented economic developing districts according to their
gross domestic product(GDP) contribution in 2006[36].
All of the 4 districts had performed DOTS strategy well,
had educated personnel and equipped laboratories. Fig-
ure 1 shows precise locations of the 4 districts and sam-
pled counties. The total number of sampled counties was
52, 14 for each in Guangxi, Jilin, Zhejiang, and 10 in
Chongqing. The counties were chosen randomly from all
eligible counties in each setting district.
Sample size assessment
We adopted stratified, cluster and probability propor-
tional to size (PPS) sampling strategy. For the start, we
calculated a sample size under the assumption of simple
random sampling in infinite population, using parame-
ters and formula as follows:
P: The expected incidence of overall ADRs, 12% was
used according to our previous systematic review [12].
d: Absolute Precision, here we took 2%.
1-α: Confidence level, we set 1-α = 95%, and uα = 1.96.
Then to correct for the cluster sampling design, n1 was
multiplied by the design effect (deff). We assumed the
average size of the clusters M was 80. But since we
couldn't find reliable assumption of interclass correlation
coefficient in TB patients group, we couldn't calculate deff
precisely, so it was simply set to be 2.
Once again we enlarged n2 by 2 for we might need to do
stratified analysis of some binary variables after all
research data would have been collected.
Finally, the number was increased by 10% considering
expected losses.
So the ultimate anticipatory sample size was deter-
mined to be 4500 and the number of cluster nc  was
approximately 56. We grouped 4 districts into 4 strata,
and then allocated 14 clusters (counties) and 1125
patients to each stratum. But since Chongqing Munici-
pality has fewer counties for randomising, its clusters
were reduced to 10 and the total clusters were 52. In the
end, the average size of our clusters was 87. In each
c o u n t y  h o w  m a n y  pa rt i ci pa n ts  s h o u l d  be  s a m p l ed  was
then decided using PPS without replacement sampling
technique, in accordance with the proportion of number
of the counties' new reported sputum smear-positive TB
patient in 2006.
Participant eligibility and recruitment
The study recruitment began in October 2007 and fin-
ished by June 2008. In the sampled 52 counties, the local
CDC investigators recognized all primary or re-treat-
ment sputum smear positive pulmonary TB patients who
would accept CNTS free treatment there as potentially
eligible participants. If patients met the inclusion and
exclusion criteria (Table 1), investigators would explain
the study to those patients, invite them for participation.
If the patients were eligible but not recruited, reasons
should be recorded. During the follow up, if patients took
a withdrawal from the study actively or passively in accor-
dance with the withdrawal criteria, reasons would also be
logged.
During the recruitment phase, 6460 smear positive
patients were recognized in our 52 study fields, 6305
patients were eligible and 4488 of them were recruited.
The participation rate of eligible subjects was 71.2%.
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Number of primary and re-treatment TB patients were
3820 and 668 respectively.
Follow-up procedures
T h e  w h o l e  s t u d y  s c h e m e  i s  d e m o n s t r a t e d  b y  f i g u r e  2 .
Several phases of data collection were envisaged for this
study.
Firstly, participants recruited would finish the baseline
questionnaire and receive several physical and laboratory
examinations, including weight, height measurement,
blood, urine routine test, liver, renal function test and
hepatitis B surface antigen (HBsAg) test. All tests were
done in local CDC laboratory using uniform reagents and
equipments corrected with standard sample from
National CDC lab. A drop of intravenous blood for each
patient from the laboratory examination blood sampling
was taken and saved in Whatman FTA card [37] for
future genetic analysis and DNA banking.
Then a follow up for 6-9 months was started. For pri-
mary TB patients it was 6 months, while for re-treatment
TB patients it was 8 months. The first 2 months were
defined as initial intensive phase, in which primary and
re-treatment patients would take HRZE and HRZES
combination respectively. The afterwards 4 or 6 months
were consolidation phase, in which they would take HR
and HRE combination respectively. If patient extended
intensive phase by 1 more month, follow up period would
prolong 1 month correspondingly. Since basically every
patient would come to local CDC monthly to pick up
their anti-TB drugs for next month' use, the local CDC
doctors could get direct contact with them at least once a
month and receive reports from supervising doctors from
time to time.
One month after anti-TB treatment started, patients
should take blood routine test, liver and renal function
test again. For all participants, ADACS program provided
these 2 times of free laboratory examinations. Partici-
pants with suspicious ADRs who were referred as adverse
drug events (ADEs) patients would have another free
examinations after ADEs happened. In spite of those
scheduled examinations, patients might also take medical
tests of other kinds or in other times personally in general
hospitals, their results would be recorded and assessed in
a later stage to be decided approved or not.
During the follow up period, patients should fill in their
ADACS calendars which were designed to record
patients' everyday feelings and their drug usages. Once
patients had unbearable discomfort, they should report it
to their supervising doctors or CDC doctors, do exami-
nations needed in time. According to DOTS, TB patients'
supervising doctors were supposed to watch patients
taken their drugs every other day although in some places
Table 1: Inclusion, exclusion and withdrawal criteria for 
participants in the ADACS program
Criteria Detailed items
Inclusion criteria 1. Primary or re-treatment sputum smear 
positive pulmonary tuberculosis patients;
2. Receiving standardized short course 
chemotherapy recommended by CNTS in local 
CDC;
3. Willing to join the study and signing the 
informed consent by himself or surrogate.
Exclusion criteria 1. Having psychiatric disease which induces 
incorporation of questionnaire investigation;
2. Having severe diseases with prognosis 
shorter than 6 months;
3. Having certain problems with signing 
informed consent;
Withdrawal criteria 1. Unwilling to keep on participating in the 
study;
2. Incompliance like stopping taking CNTS 
drugs more than 2 months;
3. Developing diseases in the exclusion criteria 
after enrollment;
4. Out-migrating or temporarily going out, 
missing the scheduled laboratory examination;
5. Death which is not caused by anti-TB drugs 
induced ADR.
Figure 2 Flow chart of ADACS implementing scheme.
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they might only do this once a week. They would super-
vise patients' drug reactions and check their ADACS fol-
low up calendars. If they assumed patients may have
ADRs, they would refer patients to CDC doctors for fur-
ther examinations and ADEs investigations. On the other
hand, if a patient didn't develop any discomfort, but his
scheduled examinations showed abnormity, the ADEs
investigation procedure would also be activated.
For identifying anti-TB induced ADEs, we had coopera-
tion with Center for Drug Reassessment (CDR) of Chi-
nese SFDA and adopted their principle, "report on
suspicious". That meant an ADE would be reported
under two conditions. The first one was when a patient
developed sign or symptom which called for medication.
The second one was the patient did not need medication
but altered his anti-TB treatment due to ADE. The ADE
would be reported to both study investigator and
National ADR monitoring system online. SFDA CDR
would then check the report, evaluate the causality of
drugs and events, approve it to be an ADR or just an
ADE. The causality assessment was following standards
of WHO Uppsala Monitoring Centre system [38], which
mainly based on drug characteristic, time sequence of
drug taken and adverse event, reaction of cutting dose,
stopping or reintroducing the suspicious drug and exis-
tence of other possible causes. Ultimately the causality of
ADE and anti-TB drug would be labeled as certain, prob-
able/likely, possible, unlikely, conditional/unclassified or
unassessible/unclassifiable. For ATLI, there was a
detailed grading diagnosis criteria which were produced
by SFDA CDR, based on Alanine transaminase (ALT)
performance.
After an ADE was identified, investigator should trace
and inquire patient about ADE treatment, prognosis,
impaction on anti-TB treatment drug change, drug with-
drawal, then fill them in the study file. Economical data
should be collected around 1 month after ADE happened
to make sure that medication costs had been paid, yet still
remembered clearly. Medical records and charging bills
o f  b o t h  o u t p a t i e n t  v i s i t  a n d  h o s p i t a l  s t a y  s h o u l d  b e
checked. Health insurance payment and self payment
should be distinguished and recorded. Those treatment,
prognosis, impact and cost inquiries should be done
again when the whole anti-TB therapy ended. Different
ADEs in one person would be recorded separately. Same
ADE in different time in one person which was proved to
be re-occurrence would also be recorded separately.
If the suspected ADR was ATLI, a nested case-control
study would be performed which comprised choosing a
matched control and doing a plus questionnaire inquiry
for both ATLI patient and control. The selection of con-
trol complied with 3 rules: 1) same sex with case; 2) age
difference from case less than 5 years; 3) primary or re-
treatment patient as case. The plus questionnaire has 3
components: surveillance of TB treatment, patient's life-
style risk factors, and patient's knowledge of TB and their
faith in current treatment.
When patient finished the standard anti-tuberculosis
therapy, their tuberculosis outcomes were recorded. The
blood samples collected previously were processed in the
central laboratory in Peking University for genotyping.
Data collection
During the study, most information was obtained by
interviewing participants in person by the local CDC
investigators. The whole process of TB treatment and its
outcome were also recorded by CDC investigators. Physi-
cal, laboratory examinations and genotyping results were
logged by lab technicians from CDC and Peking Univer-
sity. Our main investigation instruments and variables are
summarized in table 2 and table 3.
Statistical methods
Incidence and prognosis of ADRs will be reported by
descriptive statistics. Some conventional and special
approaches such as multi-lever analysis and propensity
score matching will be adopted for detecting environ-
mental and genetic factors' associations with anti-tuber-
culosis induced ADRs and their interactions. The health
economical data will be used for economical burden cal-
culation and cost-effect analysis together with local
socio-economic data.
Ethical aspects
This study was approved by the ethics committee of Cen-
ter for Tuberculosis Control and Prevention of China and
Health Sciences Center of Peking University. Oral
informed consent was obtained from every participant
before their enrollment. Meanwhile written informed
consent was signed by every study participant or surro-
gate. All participants would receive feedback reports and
suggestions about their own health status after routinely
laboratory examination, and participants with untreated
conditions identified by the examination would also be
referred to an appropriate healthcare provider.
To protect participants' privacy, no individual informa-
tion, including genetic data would be informed. Personal
identifiers, together with participants' name, Chinese ID
card number, telephone number and home address would
form a single database which only be used for contacting
participants when further information needed. Every
investigator who has access to field investigation data and
genetic data is blinded to the PID database.
Discussion
The ADACS adopted a standard longitudinal design, rep-
resented one of the largest and most diverse cohort of
patients receiving WHO recommending anti-TB treat-
ment. Thus, the major strength of this cohort is that ourXia et al. BMC Public Health 2010, 10:267
http://www.biomedcentral.com/1471-2458/10/267
Page 6 of 9
large sample size, diverse fields and intensive follow-up
will enable us to determine rates of anti-TB induced
ADRs accurately and generalize the result to similar pop-
ulations under certain conditions.
As outcome variable, ADR's determination is very
important. The previous studies of ADRs seldom did
relationship assessment for suspicious drug and target
ADRs, so sometimes misjudgment of ADRs' origin cause
was inevitable. In this study, we cooperated with China
SFDA, not only promoted it to establish a diagnostic cri-
terion for ATLI recognition and grading, but also let
every ADE reported receive strictly casualty assessment
by SFDA to determine whether it was ADR or not. This
will ensure the accuracy of ADR determining and avoid
overestimating the incidences of ADRs.
We adopted county CDC as our main investigation
locations. We employed CDC doctors as field investiga-
tor. We set timing of patient examination and follow-up
fitting common anti-TB regimen time arrangement. We
let drug taken supervisors be ADRs supervisors at the
same time. All of these ensure our cohort high participa-
tion rate, retention rate and ADR promptly reporting
rate.
The integration of multiple study methods is another
feature of ADACS. For ADRs incidences estimation, we
introduced systematic review, data mining and cohort
study. In preparing phrase of the study, we wrote system-
atic reviews of anti-TB drug induced ADRs [12,33], ana-
lyzed data in ADR monitoring databases of China and
WHO. We believe that could be a comparing source and
supplement to our incidence estimation arisen from
cohort data. For ADRs risk factors study, we imple-
mented cohort study and case-control study. We mea-
sured environmental factors, genetic factors, and clinical
factors and will analyze their independent effect and
interactive effect. For ADRs impacts study, we searched
Table 2: Main investigation instruments and their components of ADACS-1
Instruments Categories Variables
Baseline questionnaire Demographic characteristics Age; Sex; Nationality; Education; Occupation; Marriage; 
Family income of last year; Health insurance, etc.
Family history Liver, renal and other disease history of family members.
Medical history and concurrent 
disease
Previous hepatitis history; Previous hepatitis virus tests 
results. Diagnosis and duration of past renal, visional, 
auditive and other chronic disease history; Allergic history; 
Concurrent chronic diseases.
TB diagnosis and previous 
treatment
Definitive diagnosis of TB; Diagnosis time; Diagnosis 
agency; Anti-TB treatment history; Anti-tuberculosis 
induced ADEs occurrence history.
Current drug usage information Product name; Production NO; Dose; Method and cost of 
anti-tuberculosis drugs and other concurrent using drugs.
Physical, laboratory examination Physical examinations Height; Weight.
Blood routine test Erythrocyte count (1012/L); Leukocyte count (109/L); 
Hemoglobin concentration (g/L); Platelet count (109/L).
Urine routine test PH value; Urine protein; Erythrocyte count; Leukocyte 
count; Urinary cylinder count.
Liver and renal function test Alanine aminotransferase (ALT, U/L); Aspartate 
aminotransferase (AST, U/L); Total bilirubin (TBIL, μmol/L); 
Blood urea nitrogen (BUN, mmol/L).
Hepatitis B virus marker HBsAg test.
Medication record Anti-TB drugs Name, commercial name, manufacturer, production 
number, usage, dosage, starting and ending time of anti-TB 
drugs, including RHZES and other supplementary anti-TB 
drugs.
Liver protective drugs Name, commercial name, manufacturer, production 
number, usage, dosage, starting and ending time of drugs 
used for preventing ATLI.
Other drugs Name, commercial name, manufacturer, production 
number, usage, dosage, starting and ending time of other 
drugs used during the anti-TB therapy, for example, 
antihypertensive drugs, hypoglycaemic drugs, etc.Xia et al. BMC Public Health 2010, 10:267
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ADRs' direct harms, their economical impacts, their
impacts on TB treatment and TB curing, and their influ-
ences to TB epidemic control. These will let us view
ADRs from a more comprehensive perspective.
There are two main weaknesses of this study. The first
one is that we only set patient to do laboratory examina-
tions at before and 1 month after TB treatment begins,
while not arranged examinations at 1 week or 2 weeks. If
a patient developed symptom within 1 month, he would
be reported as having ADE and sent for further check
promptly. But if a patient didn't have any signs or symp-
toms, and was only recognized and confirmed to be hav-
ing an ADR because of test result abnormality at 1 month,
the discovering time of ADR would be delayed. That
would influence estimation of average ADR onset time
and let it be later. We planned to calculate proportions of
such cases and made certain adjustment to lower its
influence as much as possible. The second one is the
floating population. They will add uncertainty to follow
up. Although we anticipated a rather high retention rate
according to our following methods, floating population
will still be a problem especially after they develop an
ADR, they might be more likely to stop anti-TB therapy
and be lost to follow up. In this case, ADR happening
information would be recorded, but ADR treatment and
prognosis data might be lost which would require special
and continuous effort to get contact with the patient
again.
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